Skip to main content
. 2021 Jun 3;16(6):e0252665. doi: 10.1371/journal.pone.0252665

Fig 4. Response in four patients who had rising CA125 levels during trial treatment and received palliative radiation to a non-target lesion.

Fig 4

Y-axis: CA125. X-axis: cycle number. Block arrow indicates timing of radiation administered at a dose of 8 Gray x 3 cycles. (A) CA125 trend in three patients with high-grade serous ovarian cancer demonstrates continuing rise in CA125 levels after receiving radiation treatment. (B) Following palliative radiation, one patient with clear cell ovarian cancer demonstrated decline and normalization of CA125 levels as well as shrinkage of lesions outside of the radiation field and conversion or RECIST 1.1 response from SD to PR, suggesting potential induction of an abscopal response.